Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Shield Therapeutics ( (GB:STX) ) has issued an update.
Shield Therapeutics has granted its chief executive, Anders Lundstrom, options over 5,162,294 ordinary shares under its Retention and Performance Share Plan, equivalent to about 0.48% of the company’s AIM-listed share capital. The options, priced at 7.9p per share, will vest in three years conditional on Lundstrom remaining in post, underscoring the group’s use of equity-based incentives to retain leadership as it builds the global franchise for its iron deficiency treatment ACCRUFeR/FeRACCRU.
The award adds to Lundstrom’s existing holding of 585,000 shares and aligns his interests more closely with those of shareholders during a key commercial expansion phase. By tying a meaningful but non-dilutive proportion of equity to long-term service, Shield is seeking to reinforce executive commitment while it pursues broader market penetration for its flagship oral iron therapy in the U.S. and through partners internationally.
The most recent analyst rating on (GB:STX) stock is a Buy with a £0.10 price target. To see the full list of analyst forecasts on Shield Therapeutics stock, see the GB:STX Stock Forecast page.
Spark’s Take on STX Stock
According to Spark, TipRanks’ AI Analyst, STX is a Neutral.
The score is held back primarily by weak financial quality (ongoing losses, negative operating/free cash flow, and negative equity), partially offset by improving revenue/margins and moderately constructive price trend signals. Valuation is also constrained by loss-making status and lack of dividend support.
To see Spark’s full report on STX stock, click here.
More about Shield Therapeutics
Shield Therapeutics is a commercial-stage specialty pharmaceutical group focused on treating iron deficiency and iron deficiency anemia with its oral ferric maltol product, marketed as ACCRUFeR in the U.S. and FeRACCRU in other regions. The company targets a sizeable iron deficiency market through direct U.S. commercialization and licensing deals across Europe, Canada, Asia-Pacific and selected Asian territories, with patent protection extending into the mid‑2030s.
Average Trading Volume: 2,074,969
Technical Sentiment Signal: Hold
Current Market Cap: £84.41M
Find detailed analytics on STX stock on TipRanks’ Stock Analysis page.